{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:24:37Z","timestamp":1793381077403,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T00:00:00Z","timestamp":1713052800000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR077073"],"award-info":[{"award-number":["K23AR077073"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U54-CA225088"],"award-info":[{"award-number":["U54-CA225088"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35GM142879"],"award-info":[{"award-number":["R35GM142879"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH2110819"],"award-info":[{"award-number":["W81XWH2110819"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jaad.2022.12.048","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T03:40:31Z","timestamp":1675309231000},"page":"1024-1032","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":86,"title":["Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study"],"prefix":"10.1016","volume":"88","author":[{"given":"Shijia","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihong","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nga","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Ugwu-Dike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel","family":"Raval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayhyun","family":"Seo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora A.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruple","family":"Jairath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Phillipps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie W.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Roster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hensin","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shadmehr","family":"Demehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole R.","family":"LeBoeuf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry L.","family":"Reynolds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Hsing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Gusev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-3094","authenticated-orcid":false,"given":"Yevgeniy R.","family":"Semenov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jaad.2022.12.048_bib1","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.048_bib2","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3899\/jrheum.190084","article-title":"Immune-related adverse events associated with cancer immunotherapy: a review for the practicing rheumatologist","volume":"47","author":"Jamal","year":"2020","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.12.048_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"17","key":"10.1016\/j.jaad.2022.12.048_bib4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jaad.2022.12.048_bib5","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2022.12.048_bib6","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2021.11.050","article-title":"Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors","volume":"87","author":"Hirotsu","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2022.12.048_bib7","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1016\/j.jaad.2021.01.054","article-title":"Limitations of morphology-based management for immune checkpoint inhibitor-related cutaneous adverse events","volume":"84","author":"Otto","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.048_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.12.048_bib9","first-page":"1044","article-title":"Calculating the benefits of a research patient data repository","volume":"2006","author":"Nalichowski","year":"2006","journal-title":"AMIA Annu Symp Proc AMIA Symp"},{"key":"10.1016\/j.jaad.2022.12.048_bib10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-4-94","article-title":"An electronic application for rapidly calculating Charlson comorbidity score","volume":"4","author":"Hall","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jaad.2022.12.048_bib12","doi-asserted-by":"crossref","first-page":"b5087","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.048_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/tri.13081","article-title":"An unjustified benefit: immortal time bias in the analysis of time-dependent events","volume":"31","author":"Gleiss","year":"2018","journal-title":"Transpl Int"},{"issue":"7","key":"10.1016\/j.jaad.2022.12.048_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.21037\/atm.2018.02.12","article-title":"Time-varying covariates and coefficients in Cox regression models","volume":"6","author":"Zhang","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jaad.2022.12.048_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12874-017-0405-6","article-title":"Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study","volume":"17","author":"Cho","year":"2017","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"10.1016\/j.jaad.2022.12.048_bib16","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: a United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.048_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2022.12.048_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3390\/cancers13050989","article-title":"Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not?","volume":"13","author":"Albandar","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.048_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"issue":"8","key":"10.1016\/j.jaad.2022.12.048_bib20","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: a retrospective cohort study of 6596 patients","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.048_bib21","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20192179","article-title":"Understanding adverse events of immunotherapy: a mechanistic perspective","volume":"218","author":"Burke","year":"2021","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.jaad.2022.12.048_bib22","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2022.12.048_bib23","doi-asserted-by":"crossref","first-page":"629722","DOI":"10.3389\/fimmu.2020.629722","article-title":"Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes","volume":"11","author":"Kim","year":"2021","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jaad.2022.12.048_bib24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/1346-8138.15345","article-title":"Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: a multi-institutional retrospective study","volume":"47","author":"Matsuya","year":"2020","journal-title":"J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.048_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2017","journal-title":"J Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2022.12.048_bib26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.jaad.2022.12.048_bib27","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1158\/1078-0432.CCR-20-0305","article-title":"The role of antigen spreading in the efficacy of immunotherapies","volume":"26","author":"Brossart","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.jaad.2022.12.048_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2217\/imt.11.62","article-title":"Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients","volume":"3","author":"Hardwick","year":"2011","journal-title":"Immunotherapy"},{"issue":"581","key":"10.1016\/j.jaad.2022.12.048_bib29","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.jaad.2022.12.048_bib30","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1046\/j.1523-1747.1998.00107.x","article-title":"Epitope spreading: lessons from autoimmune skin diseases","volume":"110","author":"Chan","year":"1998","journal-title":"J Invest Dermatol"},{"issue":"6746","key":"10.1016\/j.jaad.2022.12.048_bib31","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/23495","article-title":"The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells","volume":"400","author":"Campbell","year":"1999","journal-title":"Nature"},{"issue":"6654","key":"10.1016\/j.jaad.2022.12.048_bib32","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/40166","article-title":"Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells","volume":"389","author":"Fuhlbrigge","year":"1997","journal-title":"Nature"},{"issue":"7388","key":"10.1016\/j.jaad.2022.12.048_bib33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature10851","article-title":"Skin infection generates non-migratory memory CD8+ T(RM) cells providing global skin immunity","volume":"483","author":"Jiang","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.jaad.2022.12.048_fur1","doi-asserted-by":"crossref","unstructured":"Chen S, LeBoeuf N, Reynolds K, Semenov Y. 1263 Dermatologic immune related adverse event disease definitions: a multi-institutional Delphi consensus project presented on behalf of the oncodermatology working group. BMJ. 2022;10:A1309.","DOI":"10.1136\/jitc-2022-SITC2022.1263"},{"issue":"1","key":"10.1016\/j.jaad.2022.12.048_fur2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/001316446002000104","article-title":"A coefficient of agreement for nominal scales","volume":"20","author":"Cohen","year":"1960","journal-title":"Educ Psychol Meas"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223001536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962223001536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:19:16Z","timestamp":1782487156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962223001536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0190962223001536"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.12.048","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.01.16.23284635","asserted-by":"object"}]},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.12.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}